A "Calibrated Approach": Pharmaceutical FDI and the Evolution of Indian Patent Law

Linton, Katherine Connor; Corrado, Nicholas
August 2008
Journal of International Commerce & Economics;Aug2008, Vol. I, p163
Trade Publication
India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs) have responded to India's movement towards compliance with the WTO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. By contrast, MNCs have adopted a more cautious attitude toward the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent offices interpret the new laws, and awaiting the enactment of longdebated data protection legislation. The ultimate success of the Indian "calibrated approach" to fostering the domestic industry and access to medicine while also addressing international IP requirements remains to be seen.


Related Articles

  • Israel Pharmaceuticals and Healthcare Report Q4 2011 -- Israel Now Reinstated on the Pharmaceutical Research and Manufacturers of America Special 301 Submission's Priority Watch List For 2011.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p538 

    The article discusses the reinstatement of Israel on the 2011 priority watch list of the Pharmaceutical Research and Manufacturers of America's Special 301 submission report. It mentions that the country magnifies high per-capita on pharmaceutical spending. It also notes that multinational firms...

  • Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. Morag-Sela, Tamar; Cohn, Ilan; Kowalski, Thomas J.; Jarecki-Black, Judy; Clyde-Watson, Zoe // Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1591 

    The article discusses issues related to intellectual property (IP) rights to pharmaceuticals in Israel. The country has a very strong generic pharmaceutical industry. Israel's past record of defending and respecting IP rights has led major companies around the world to file patent applications...

  • Caution needed for Russian Expansion.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p10 

    The article indicates that accounting and consulting firm PricewaterhouseCoopers has released a report on the opportunities and problems associated with the pharmaceutical industry in Russia. It was observed that the legal system is much weaker than in the European Union, U.S. or Japan, and that...

  • Intellectual property, pharmaceutical MNEs and the developing world. Ghauri, Pervez N.; Rao, P.M. // Journal of World Business;Apr2009, Vol. 44 Issue 2, p206 

    Abstract: The paper examines the structure of pharmaceutical R&D funding, spillovers and public�private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives...

  • Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Oliveira, Maria Auxiliadora; Bermudez, Jorge Antonio Zepeda; Chaves, Gabriela Costa; Velásquez, Germán // Bulletin of the World Health Organization;Nov2004, Vol. 82 Issue 11, p815 

    Objective The World Trade Organization's Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement establishes minimum standards for intellectual property rights, including patent protection for pharmaceuticals; therefore, it may make it difficult for developing countries to gain...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

  • Intellectual Property Laws. Stuart, Michael // Pharmaceutical Technology;Jul2006, Vol. 30 Issue 7, p94 

    The article discusses the author's insights which pertain to intellectual property laws to be applied for the protection of pharmaceutical companies from competitive challenges. Pharmaceutical companies understand the benefits and boundaries of intellectual property as their valuable group of...

  • IP: Time for a Reset? Looney, William // Pharmaceutical Executive;Apr2012, Vol. 32 Issue 4, p12 

    The article focuses on challenges facing pharmaceutical patenters with market uncertainty due to decline in patent filings, conflicting legislation for defining patentability and stalled progress on consensus to extend minimum levels of intellectual property (IP) protection. It reflects that...

  • Protecting Patents?  // Pharmaceutical Executive;Jan2008, Vol. 28 Issue 1, p30 

    The article focuses on the issues concerning the patent-reform legislation regarding pharmaceutical products in the U.S. According to the author, the main issue evolves in a postgrant review system that allows reevaluation of patents after they are awarded. As a result, pharmaceutical companies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics